sinc
initi
clinic
use
immunoglobulin
g
igg
concentr
human
origin
transmiss
pathogen
noninfecti
advers
event
ae
report
mid
transmiss
pathogen
depend
pool
size
fraction
method
use
particularli
polish
step
igg
concentr
mode
fraction
ie
coldethanol
ionexchang
chromatographi
contamin
rout
applic
ie
intra
muscular
imig
intraven
ivig
subcutan
scig
rate
increas
exogen
igg
circul
recipi
time
last
least
eventu
exist
risk
factor
patient
side
figur
well
incorrect
handl
concentr
factor
role
induc
noninfecti
ae
relat
administr
igg
concentr
tabl
igg
concentr
repres
defin
part
adapt
immun
system
isol
pool
human
plasma
least
donor
contribut
repertoir
divers
final
product
therapi
igg
concentr
manufactur
accord
regul
requir
acknowledg
safe
gener
exclud
occurr
ae
major
rare
clinic
mild
moder
like
give
insight
variou
aspect
possibl
mechan
ae
manufactur
modern
igg
concentr
occur
regulatori
framework
qualiti
standard
implement
plasma
fraction
industri
figur
cornerston
regulatori
framework
current
good
manufactur
practic
cgmp
pillar
pathogen
safeti
valid
viru
inactiv
viru
elimin
method
valid
alreadi
perform
step
fraction
process
introduct
dedic
step
figur
hallmark
viru
elimin
introduc
late
bern
team
christoph
kempf
largescal
viru
filtrat
techniqu
formerli
also
term
nanofiltr
meanwhil
viru
filtrat
becam
versatil
tool
elimin
varieti
pathogen
suspect
agent
variant
creutzfeldtjakob
diseas
includ
thank
tightli
implement
regulatori
framework
pathogen
safeti
plasma
product
level
never
reach
well
support
fact
report
miss
last
decad
transmiss
igg
concentr
emerg
virus
sar
coronaviru
west
nile
viru
mer
coronaviru
other
zoonot
pathogen
agent
variant
creutzfeldtjakob
diseas
vcjd
furthermor
develop
specif
mass
screen
techniqu
might
help
erad
blood
product
transmiss
vcjd
futur
first
report
rapid
onset
ae
concern
either
applic
complementactiv
fraction
igg
concentr
vivo
format
complementactiv
ic
rare
potenti
fatal
condit
format
igaantiiga
complex
patient
initi
replac
therapi
serum
igg
antibodi
infus
iga
recogn
start
ivig
infus
prerequisit
presenc
antiiga
antibodi
common
primari
immunoglobulin
defect
ie
select
iga
defici
sigad
igad
associ
diminut
immunoglobulin
class
igad
defin
serum
level
gl
depend
laboratori
mark
diminut
serum
iga
consist
igad
variou
ethnic
group
estim
mean
frequenc
caucasian
approxim
patient
igad
report
antiiga
antibodi
serum
titer
rang
approxim
patient
common
variabl
immunodefici
cvid
occasion
patient
primari
immunodefici
diseas
measur
antiiga
detect
antibodi
predominantli
igg
class
antiiga
antibodi
immunoglobulin
class
describ
well
reason
emerg
remain
unknown
taken
number
infus
humanderiv
product
contain
iga
result
sever
anaphylactoid
type
ae
consider
case
question
clinic
relev
number
emerg
soon
blood
bank
estim
theoret
risk
iga
anaphylact
reaction
ii
assess
relat
sever
igad
presenc
absenc
antiiga
antibodi
iii
screen
donor
low
iga
level
order
becom
abl
provid
blood
plasmaderiv
product
free
iga
find
consider
lower
frequenc
expect
altern
test
system
may
reliabl
detect
antiiga
antibodi
yet
insensit
inaccur
least
correspond
clinic
relev
fraction
antibodi
come
mind
close
look
antiiga
give
unexpect
result
includ
antiiga
blood
donor
normal
serum
iga
level
antiiga
neutral
purifi
iga
blood
product
contain
proven
antiiga
elicit
sever
ae
among
patient
replac
therapi
cvid
may
rare
develop
sever
immedi
ae
discrep
antiiga
posit
patient
frequenc
ae
rais
question
natur
mani
report
antiiga
antibodi
also
rais
question
immunolog
condit
allow
format
anaphylactoid
antiiga
antibodi
might
logic
suppos
anaphylactoid
antiiga
evolv
iga
level
otherwis
fulfil
definit
igad
condit
would
constantli
gener
ic
turn
could
activ
complement
react
immun
cell
deposit
lung
kidney
inde
horn
et
al
found
antiiga
antibodi
cvid
patient
miss
iga
b
cell
present
iga
level
gl
level
lower
threshold
igad
howev
possibl
igamedi
anaphylactoid
reaction
measur
iga
serum
level
might
exist
serum
iga
contain
approxim
subclass
iga
subclass
iga
select
defici
although
evid
lack
presenc
highli
specif
antibodi
theoret
could
elicit
sever
ae
kinet
antiiga
infus
blood
product
studi
case
patient
fall
antiiga
titer
notic
follow
increas
subsequ
week
month
suggest
appropri
proport
iga
infus
materi
antiiga
present
patient
serum
combin
form
ic
turn
ic
activ
complement
bound
elimin
macrophag
like
lead
cytokin
releas
increas
antiiga
titer
time
indic
infus
igacontain
product
booster
effect
boost
effect
togeth
presenc
antiiga
applic
igg
concentr
taken
ultim
confirm
suppos
igaantiiga
reaction
figur
depict
welldocu
case
igaantiiga
reaction
patient
progress
sigad
cvid
event
first
h
occas
first
infus
ivig
follow
shadow
area
figur
min
start
infus
receiv
eight
drop
igg
solut
iga
gl
solut
experienc
flush
back
pain
rigor
difficulti
breath
hypotens
infus
immedi
stop
approxim
h
reaction
wean
h
later
patient
felt
well
infus
total
g
igg
could
continu
without
complic
although
patient
fairli
assur
never
receiv
blood
plasma
product
past
followup
antiiga
titer
infus
year
later
confirm
true
anaphylactoid
reaction
mediat
antiiga
antiiga
becam
undetect
immedi
infus
show
boost
phenomenon
follow
month
true
anaphylactoid
reaction
confirm
followup
total
complement
hemolyt
activ
day
infus
interestingli
enough
valu
reach
nadir
end
infus
patient
complain
although
singl
case
event
first
infus
call
follow
remark
sever
ae
like
occur
concomit
complement
cell
activ
cytokin
releas
ii
infus
minut
low
amount
ivig
hour
main
infus
anerg
cell
stop
releas
proinflammatori
cytokin
iii
anerg
cell
loos
reactiv
toward
ongo
format
ic
complement
activ
product
noncomplementmedi
anaphylactoid
reaction
ascrib
unforeseen
releas
elastas
proinflammatori
substanc
neutrophil
activ
format
vivo
igaantiiga
complex
complement
activ
mast
celldepend
releas
vasoact
substanc
exclud
pathogen
mechan
although
igaantiiga
complex
usual
caus
clinic
relev
neutrophil
degranul
within
circul
presenc
rare
genotyp
encod
novel
gainoffunct
igg
receptor
neutrophil
may
provok
prematur
degranul
complex
phenomenon
relev
hypogammaglobulinem
patient
presenc
vivo
igaantiiga
complex
low
preval
genotyp
combin
igad
cvid
may
add
explain
rariti
seriou
anaphylactoid
reaction
newli
ivigtr
patient
author
share
opinion
jann
occas
discuss
panel
dilemma
diagnosi
manag
antibodi
defici
ask
expert
held
occas
annual
meet
american
academi
allergi
asthma
immunolog
aaaai
new
york
citi
march
came
follow
conclus
clinician
awar
risk
particularli
occas
first
infus
otherwis
iga
major
concern
tape
record
earli
day
igtherapi
natur
phlogist
ae
obscur
howev
alreadi
known
ae
prevent
evolut
halt
patient
receiv
low
dose
ivig
first
infus
stop
earli
continu
sever
hour
later
hour
later
infus
start
high
rate
without
problem
figur
one
author
particular
opportun
get
insight
phlogist
reaction
might
occas
voluntari
infus
investig
liquid
ivig
encount
sever
flulik
ae
h
durat
inject
investig
liquid
prepar
pass
releas
criteria
human
use
includ
spontan
complement
activ
assess
aca
free
prekallikrein
activ
pka
day
assay
cytokin
biolog
sampl
began
becom
avail
includ
paramet
assess
studi
infus
stop
h
drop
puls
rate
heavi
discomfort
provok
lacon
comment
proband
technician
take
sampl
look
green
infus
continu
anoth
min
heart
rate
almost
normal
infus
could
complet
within
addit
h
total
gkg
bw
without
aggrav
malais
leukocyt
count
transient
drop
nadir
h
follow
leukocytosi
peak
h
complement
activ
assess
gener
desarg
format
termin
complement
complex
appar
occur
desarg
valu
reach
maximum
ngml
norm
ngml
h
valu
never
move
outsid
normal
rang
instead
sequenc
rapid
transient
massiv
increas
proinflammatori
cytokin
observ
start
increas
min
post
initi
infus
valu
pgml
peak
valu
h
calibr
rang
test
kit
pgml
ii
interleukin
increas
start
h
pgml
peak
h
pgml
post
initi
infus
iii
interleukin
secret
start
h
undetect
level
peak
h
pgml
proinflammatori
cytokin
fell
sharpli
second
part
infus
still
ongo
day
infus
proinflammatori
cytokin
profil
back
normal
flulik
syndrom
gone
contrast
interleukin
receptor
antagonist
valu
start
increas
h
pgml
peak
h
pgml
decreas
slowli
reach
valu
pgml
h
initi
infus
solubl
tnf
receptor
level
start
ngml
reach
peak
ngml
time
h
initi
infus
still
ngml
thu
normogammaglobulinem
subject
similar
cytokin
profil
leukocyt
number
chang
observ
report
hypogammagobulinemia
replac
therapi
seri
experi
investig
market
ivig
perform
igg
concentr
analyz
molecular
weight
mw
distribut
remark
differ
emerg
mw
rang
dimer
presenc
minut
amount
higher
oligom
could
exclud
certainti
use
term
dimer
fraction
igg
higher
mw
subsequ
find
indic
level
dimer
respons
complementindepend
cell
activ
cytokin
releas
peak
assess
h
post
initi
infus
correl
dimer
content
ivig
mirror
clinic
score
ae
year
complementindepend
induct
hypotens
factor
igg
di
oligom
report
anim
experi
key
role
macrophag
gener
hypotens
lipid
factor
identifi
plateletactiv
factor
induc
dimer
polym
sever
year
later
dimermedi
ae
anim
experi
confirm
yet
time
dimer
content
ivig
appar
correl
clinic
efficaci
murin
itp
model
variabl
ir
genet
background
endogen
immunoglobulin
level
proport
fraction
polym
versu
dimer
may
impact
balanc
phlogiston
cytokin
activ
lipid
substanc
combin
factor
therapeut
efficaci
block
igg
receptor
liverspleen
macrophag
prevent
clearanc
opson
materi
platelet
itp
today
report
releas
cytokin
human
associ
ae
toler
toward
dimer
remain
scarc
best
knowledg
studi
human
caus
factorsfract
igg
concentr
adequ
address
igg
prepar
variou
form
dimer
might
present
form
coval
bind
denatur
hydrophob
interact
fcpart
idiotypeantiidiotyp
interact
part
vconnect
network
peripher
immun
homeostasi
commerci
viabl
fraction
process
pool
donat
plasma
mandatori
order
obtain
volum
start
materi
larg
enough
cover
ever
increas
cost
document
inprocess
batchreleas
test
requir
cgmp
pool
also
intend
smooth
batchtobatch
differ
antibodi
titer
goal
appar
difficult
achiev
level
theori
might
impli
consequ
pool
one
hand
enrich
publiccommon
immun
antibodi
dilut
individu
specif
hand
antibodi
immun
network
individu
donor
expos
mani
donor
individu
contribut
pool
complex
possibl
immunenetwork
interact
among
iga
igg
igm
becom
subsequ
fraction
process
farreach
effect
immunoglobulin
given
pool
trace
amount
iga
igm
retain
final
product
ie
igg
depriv
counterpart
vconnect
immun
network
igg
molecul
homeostat
network
nake
vregion
interact
random
combin
siteinteract
singl
donorderiv
monomer
igg
otherwis
exist
vivo
interact
larg
revers
increas
number
donor
includ
pool
immun
network
recognit
among
nake
igg
molecul
vconnect
network
becom
complex
dimer
lower
oligom
content
result
igg
concentr
increas
lyophil
igg
concentr
dimer
format
frozen
low
level
liquid
prepar
equilibrium
monom
dimer
achiev
time
reach
dimer
content
hamper
stabil
specif
far
address
dimer
fraction
consider
differ
monomer
fraction
conclus
immunomodulatori
efficaci
igg
concentr
part
depend
capac
extent
form
dimer
fraction
devoid
remark
complement
activ
vivo
art
manufactur
liquid
igg
concentr
elimin
monomer
igg
potenti
dimer
format
inhibit
extens
dimer
summari
ae
might
associ
induct
proinflammatori
cytokin
absenc
measur
complement
activ
vivo
regulatori
mechan
remov
process
bodi
disposit
reason
ir
open
system
human
bodi
clinic
relev
system
complement
activ
appar
need
oligom
form
three
igg
molecul
detect
immunomodulatori
potenti
igg
concentr
clinic
use
continu
increas
cover
need
first
glanc
increas
volum
plasma
fraction
seem
conveni
option
howev
might
econom
viabl
fraction
plasma
product
interconnect
increas
output
one
product
eg
ivig
market
absorb
product
well
eg
albumin
must
ascertain
longerrun
viabl
option
improv
recoveri
consid
recoveri
coldethanol
fraction
appar
reach
limit
today
four
manufactur
invest
modern
fraction
techniqu
basi
ionexchang
chromatographi
ionexchang
chromatographi
allow
elev
recoveri
high
puriti
today
five
ivig
one
scig
one
antid
concentr
fraction
ionexchang
chromatographi
pharmacovigil
shown
chromatograph
fraction
ivig
scig
less
promin
show
tendenc
elev
frequenc
hemolyt
ae
antia
antib
alloantibodi
titer
lotreleas
criteria
see
constitut
major
risk
paramet
hemolyt
reaction
mediat
igg
concentr
overcom
threat
end
dark
side
moon
two
manufactur
taken
measur
reduc
antia
antib
titer
igg
product
one
measur
chosen
adsorpt
alloantibodi
affin
chromatographi
report
reduct
alloantibodi
signific
level
similar
coldethanol
fraction
immunoglobulin
measur
chosen
reduct
antia
use
autom
indirect
agglutin
test
donor
screen
exclus
hightit
donat
approxim
plasma
pool
fraction
measur
reduc
antia
igg
concentr
one
titer
step
ensur
stay
safe
sunni
side
manufactur
announc
introduct
alloantia
alloantib
immuneaffin
chromatographi
step
manufactur
process
preliminari
result
indic
deplet
antia
antib
investig
lot
subsequ
want
discuss
possibl
consequ
extens
remov
antibodi
react
histoblood
group
antigen
b
three
fact
initi
think
possibl
consequ
remov
histoblood
group
b
react
antibodi
igg
concentr
collabor
han
u
lutz
formerli
biochemistri
eth
zurich
observ
nonintend
remov
natur
autoantibodi
regul
complement
activ
largescal
immuneaffin
adsorpt
iga
igg
concentr
antibodi
belong
famili
nab
particular
role
homeostasi
control
activ
complement
among
other
frame
nabmedi
opsonophagocytosi
alter
senesc
cell
includ
rbc
thu
intent
target
one
particular
antibodi
affin
chromatographi
might
reduc
antibodi
specif
time
affect
specif
well
ii
kept
mind
blood
group
b
fact
histoblood
group
antigen
ie
also
found
white
blood
cell
lymphocyt
protein
also
found
solubl
form
alloantibodi
react
histoblood
group
antigen
b
thu
much
broader
tissu
recognit
rbc
addit
alloantia
alloantib
belong
popul
nab
recogn
nonself
like
particip
primari
host
defens
iii
contrast
coldethanol
fraction
low
titer
alloantia
alloantib
achiev
basi
isoelectr
point
iep
extens
immuneaffin
remov
might
affect
much
wider
iep
rang
therebi
remov
broadli
react
antibodi
impair
desir
function
igg
concentr
thu
struggl
stay
sunni
side
moon
might
consequ
antibodi
repertoir
igg
concentr
antibodi
react
termin
di
tri
tetrasaccharid
belong
larg
famili
human
antiglycan
nab
histoblood
group
b
epitop
termin
posit
tetrasaccharid
alloantibodi
tetrasaccharid
found
plasma
healthi
individu
depend
blood
group
consider
bodi
research
natur
nab
perform
far
use
isol
correspond
termin
di
trisaccharid
recent
repertoir
epitop
specif
immunoglobulin
address
depth
includ
tetrasaccharid
well
prove
serum
healthi
individu
contain
respect
amount
di
trisaccharidereact
nab
nab
prove
pseudoantia
pseudoantib
nab
react
tetrasaccharid
histoblood
group
b
contrast
alloantia
b
antibodi
abl
react
tetrasaccharid
react
correspond
termin
di
trisaccharid
reason
biolog
role
hightit
popul
conserv
antidi
antitrisaccharid
nab
consequ
potenti
remov
immunoaffin
outlin
popul
antiglycan
nab
nab
recogn
gal
epitop
nab
describ
xenoreact
recogn
bacteri
tissu
homeostat
function
daili
remov
alteredsenesc
cell
bodi
remov
mainli
mediat
apoptosi
inflamm
necrosi
rbc
encount
patholog
condit
life
span
day
remain
intact
although
shrink
undergo
apoptosi
progress
becom
senesc
mainli
due
cumul
oxid
stress
remov
intact
rbc
daili
turnov
correspond
g
cell
mass
effectu
increas
exposur
otherwis
cryptic
structur
spectrin
band
epitop
expos
structur
recogn
low
affin
high
avid
nab
promot
effici
remov
intact
senesc
rbc
immunoaffin
adsorpt
trisaccharid
column
di
trisaccharid
react
nab
igg
concentr
elimin
antihistoblood
b
alloantibodi
also
elimin
might
janu
effect
face
direct
sun
tell
adsorb
nab
react
alter
senesc
self
rbc
might
prevent
increas
igg
load
rbc
threshold
level
relev
hemolysi
individu
risk
face
direct
dark
indic
adsorpt
tissu
homeostat
antibodi
might
depriv
igg
concentr
potenti
benefici
antibodi
although
nab
trisaccharid
react
antibodi
induc
feed
bacteria
bear
correspond
carbohydr
epitop
induc
nab
consid
particip
primari
host
defens
antibodi
possibl
involv
primari
host
defens
nab
show
broad
specif
react
number
relat
oligosaccharid
includ
bacteria
thu
immunoadsorpt
diand
trisaccharid
react
nab
might
diminish
potenti
igg
concentr
mediat
primari
host
defens
therefor
choos
affin
resin
immunoadsorpt
might
aspect
worth
consid
summari
principl
avoid
cofraction
coldethanol
fraction
versu
immuneaffin
remov
histoblood
group
alloantibodi
impact
presenc
homeostat
firstlin
defens
antibodi
accord
present
knowledg
resin
coat
correspond
tetrasaccharid
ascertain
select
remov
histoblood
group
alloantibodi
presum
involv
ha
resin
coat
correspond
di
trisaccharid
also
remov
blood
group
alloantibodi
howev
select
resin
addit
might
remov
broad
rang
nab
present
igg
concentr
rel
high
amount
literatur
use
trisaccharideco
resin
report
found
inform
avail
public
domain
indic
type
resin
iswil
use
reduct
histoblood
group
alloantibodi
largescal
fraction
igg
furthermor
suggest
effect
reduct
antia
antb
react
antibodi
immuneaffin
antibodi
repertoir
igg
concentr
assess
eg
use
pathogenscommens
share
saccharid
epitop
use
coat
affin
resin
altern
expos
senesc
rbc
strip
igg
coat
vivo
final
techniqu
requir
allow
detect
low
affin
high
avid
nab
ivig
administrationrel
ae
includ
thrombosi
extens
describ
thrombot
ae
sever
ae
patient
risk
factor
requir
special
care
report
averag
incid
iviginduc
thrombosi
rang
recogn
risk
factor
iviginduc
thrombosi
includ
male
gender
age
diabet
renal
insuffici
dyslipidemia
hypertens
immobl
coronari
diseas
preexist
vascular
diseas
famili
histori
earli
thromboembol
diseas
atrial
fibril
highdos
highspe
ivig
infus
iviginduc
thrombosi
report
venou
event
thrombosi
stroke
pulmonari
embol
pe
deep
venou
thrombosi
dvt
arteri
ischemia
event
myocardi
infarct
stroke
mechan
lead
ivigassoci
thrombosi
still
complet
clear
three
main
mechan
propos
emphas
role
increas
blood
viscos
caus
hypercoagul
state
role
anticardiolipin
antibodi
passiv
transfer
ivig
role
factor
xia
biolog
highli
activ
factor
passiv
transfer
via
igg
concentr
pka
avoid
activ
coagul
factor
igg
concentr
start
appropri
anticoagul
donat
bloodplasma
ie
care
mix
anticoagul
sampl
whole
donat
process
alter
establish
manufactur
process
neglect
appropri
control
also
lead
increas
risk
transmiss
activ
coagul
factor
high
mw
protein
passiv
transfer
ivig
probabl
contribut
phenomenon
patient
risk
factor
vascular
diseas
increas
blood
viscos
precipit
thromboembol
event
elderli
individu
prone
ae
like
point
possibl
elev
alteredsenesc
selfreact
infus
homeostat
nab
possibl
factor
facilit
thrombot
event
well
relationship
ivig
administr
cerebr
vasospasm
also
suggest
sztajzel
et
al
blood
viscos
determin
oxygen
deliveri
tissu
chang
viscos
lead
reduct
cerebr
myocardi
perfus
systemat
review
case
report
relat
iviginduc
thrombosi
figur
literatur
search
identifi
articl
contain
report
concern
patient
data
avail
diagnosi
risk
factor
number
ivig
infus
prior
thrombosi
event
outcom
indic
baselin
characterist
patient
shown
tabl
highdos
ivig
induc
thromboembol
event
patient
low
medium
ivig
dose
mari
et
al
observ
frequenc
type
arteri
event
invers
relat
time
elaps
ivig
infus
almost
versu
report
arteri
ischem
event
occur
within
h
follow
ivig
venou
thrombosi
occur
h
correl
number
infus
occurr
ae
observ
main
risk
factor
observ
review
hypertens
case
preval
previou
vascular
diseas
dyslipidemia
averag
mortal
thrombot
event
arteri
ischemia
versu
venou
thrombosi
pe
repres
main
venou
fatal
event
predict
iviginduc
thrombosi
difficult
risk
factor
assess
patient
includ
instrument
exam
need
doppler
ultrasound
use
earli
diagnost
tool
thrombosi
detect
presenc
abnorm
blood
flow
especi
prolong
immobl
ivig
administ
low
ir
reduc
risk
administr
antiplatelet
anticoagul
prophylaxi
suggest
patient
sever
risk
factor
howev
thrombot
event
report
even
sever
previou
uncompl
cours
treatment
case
patient
examin
sign
symptom
thrombosi
cours
ivig
immunoglobulin
g
concentr
wide
acknowledg
offer
safe
highdos
longterm
therapi
option
varieti
diseas
ae
occur
rare
mainli
mild
moder
deviat
rule
thumb
address
author
plasma
fraction
industri
achiev
correct
review
two
type
ae
shown
elev
frequenc
near
past
tri
give
insight
might
help
reduc
frequenc
ae
bed
side
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
